EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti‐HER2 Antibodies and Immunotherapy

Panagiotis Sarantis iD, Aristofania Simatou, Ioanna A Anastasiou iD, Kostas Palamaris, Eleni-Myrto Trifylli, Evangelos Koustas, Christina Piperi, Michalis V Karamouzis, Athanasios G Papavassiliou

Journal of Cellular and Molecular Medicine · 2026-02 · 30 (4)

DOI: 10.1111/jcmm.71071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 23.02.2026. Verfasst von Panagiotis Sarantis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Denosumab, Immunotherapy. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in targeted therapies, resistance to anti‐human epidermal growth factor receptor 2 (HER2) treatments remains a significant challenge in breast cancer (BC) management. This study aimed to evaluate the effectiveness of a triple‐targeting regimen—Denosumab (D), Pertuzumab (P) and Trastuzumab (T)—for HER2‐positive (HER2 + ) BC, and to assess the added value of immune checkpoint inhibitors (ICIs). Immunohistochemical analysis of 120 paraffin‐embedded BC samples revealed that HER2 + tumours exhibited significantly higher receptor activator of nuclear factor (NF)‐κB (RANK) expression compared to HER2‐negative (HER2 − ) tumours. Notably, RANK‐positive (RANK + )/HER2 + patients who received triple‐targeting therapy experienced a statistically significant improvement in disease‐free survival (DFS), while RANK‐negative (RANK − )/HER2 + patients did not derive similar benefit. In BT‐474 HER2 + xenograft mouse models, the combination of D+P+T significantly reduced tumour volume and weight. Additional analyses showed elevated signal transducer and activator of transcription 3 ( STAT3 ) expression in HER2 − tissues and higher mechanistic target of rapamycin ( mTOR ) expression in HER2 − compared to HER2 + samples. Importantly, three‐dimensional (3D) cell culture experiments demonstrated that adding ICIs (Nivolumab (N) and Ipilimumab (I)) to the triple‐targeting regimen further reduced cell viability in HER2 + BC cells. These results underscore the pivotal role of the RANK–receptor activator of NF‐κB ligand (RANKL) axis in tumour growth and immune regulation, supporting the use of triple‐targeting therapy and suggesting enhanced benefits with the inclusion of ICIs to potentially overcome therapeutic resistance in HER2 + BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsDenosumabImmunotherapyReceptor Activator of Nuclear Factor-kappa BHumansFemaleAnimalsMiceAntibodies, Monoclonal, HumanizedCell Line, TumorXenograft Model Antitumor AssaysTrastuzumab

Stichwörter der Autor:innen

DenosumabHER2PertuzumabRANKRANKLTrastuzumabbreast cancerimmune checkpoint inhibitors

Substanzen

Erb-b2 Receptor Tyrosine KinasesDenosumabReceptor Activator of Nuclear Factor-kappa BERBB2 protein, humanAntibodies, Monoclonal, HumanizedTrastuzumabpertuzumabTNFRSF11A protein, human

Autor:innen und Institutionen

  • Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Second Department of Internal Medicine-GI-Liver Unit, General Hospital 'Hippokratio', Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Oncology Department, General Hospital 'Evangelismos', Athens, Greece.
  • Academic Department of Internal Medicine, General and Oncology Hospital 'Agioi Anargyroi', National and Kapoditrian University of Athens, Athens, Greece.

ORCID-Profile: Panagiotis Sarantis, Ioanna A Anastasiou

Zitieren

APA

Sarantis, P., Simatou, A., Anastasiou, I. A., Palamaris, K., Trifylli, E. M., Koustas, E., Piperi, C., Karamouzis, M. V., & Papavassiliou, A. G. (2026). The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti‐HER2 Antibodies and Immunotherapy. Journal of Cellular and Molecular Medicine, 30(4). https://doi.org/10.1111/jcmm.71071

Vancouver

Sarantis P, Simatou A, Anastasiou IA, Palamaris K, Trifylli EM, Koustas E, et al. The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti‐HER2 Antibodies and Immunotherapy. Journal of Cellular and Molecular Medicine. 2026;30(4). doi:10.1111/jcmm.71071

BibTeX
@article{Sarantis2026,
  author = {Sarantis, Panagiotis and Simatou, Aristofania and Anastasiou, Ioanna A and Palamaris, Kostas and Trifylli, Eleni-Myrto and Koustas, Evangelos and Piperi, Christina and Karamouzis, Michalis V and Papavassiliou, Athanasios G},
  title = {The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti‐HER2 Antibodies and Immunotherapy},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {4},
  doi = {10.1111/jcmm.71071}
}
Kostenlos starten →